On Thursday, Shares of Civeo Corporation (NYSE:CVEO), gained 5.76% to $3.49.
Civeo Corporation, declared that it has planned its first quarter 2015 earnings conference call for Thursday, April 30, 2015 at 11:00 am Eastern time. During the call, Civeo will talk about the results for the quarter ended March 31, 2015, which are predictable to be released on April 29, 2015, after markets close.
Civeo Corporation provides remote site accommodations for the natural resource industry in Australia, Canada, and the United States. It also offers facility administration services, counting food services.
Shares of BJ’s Restaurants, Inc. (NASDAQ:BJRI), gained 5.74% to $53.44, during its last trading session.
BJ’s Restaurants, stated financial results for its fiscal 2015 first quarter that ended on Tuesday, March 31, 2015.
First Quarter 2015 Highlights Contrast to First Quarter 2014
- Total revenues raised 9.4% to $225.1 million
- Total restaurant operating weeks raised about 7%
- Comparable restaurant sales raised 3.2%
- Net income raised to $9.6 million from $4.7 million
- Diluted net income per share raised to $0.36 from $0.16 (first quarter 2014 diluted net income per share of $0.16 was inclusive of a $0.04 diluted net income per share charge related to shareholder settlement costs).
BJ’s Restaurants, Inc. owns and operates casual dining restaurants in the Unites States. The company’s restaurants offer pizzas, beers, appetizers, entrees, pastas, sandwiches, salads, and desserts.
At the end of Thursday’s trade, Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), gained 5.71% to $16.95, hitting its highest level.
Halozyme Therapeutics, shared highlights of new data it presented at the American Association for Cancer Research (AACR) annual meeting. Halozyme also declared plans to present interim results of its randomized Phase 2 study in pancreatic cancer, Study 202, next month at the annual meeting of the American Society of Clinical Oncology (ASCO).
In an oral presentation at the AACR meeting titled “Hyaluronan (HA) Depletion Enhances Tumor Accessibility of T cell and Therapeutic PD-L1 Monoclonal Antibody in HAhigh Tumors,” findings in an animal model of non-small-cell lung cancer comprised of:
- Tumors with high levels of HA – a structural carbohydrate that accumulates in the areas surrounding cancer cells -form a natural HA-rich barrier that restricted T-cell access to tumor cells;
- Halozyme’s investigational new drug, PEGPH20, depletes HA and enhances T-cells access to tumor cells in an animal models;
- HA removal by PEGPH20 improved anti-PD-1 or anti-PD-L1 dependent tumor-cell killing in cell based assays;
- HA depletion by PEGPH20 raised the access of T cell and anti-human PD-L1antibody in HA-high xenograft tumors, suggesting that PEGPH20 may have the potential to enhance the efficacy of immune checkpoint inhibitors in human HA-high tumors.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
Finally, Cablevision Systems Corporation (NYSE:CVC), ended its last trade with 5.43% gain, and closed at $19.41.
Cablevision Systems Corporation, declared the launch of new Internet-focused Optimum product offers that provide greater choice and flexibility for the ‘cord cutter’ and ‘cord never’ generation of connectivity-minded consumers.
With market behavior evolving, Cablevision is expanding its product offerings to meet customers where they are. ‘Cord cutters’ and ‘cord nevers,’ who prefer to access video through the Internet, can now easily self-select the broadband products they want and receive over-the-air broadcast TV through a digital antenna*. The most price-sensitive consumers will have access to a new ‘Everyday Low Price’ three-product package designed to fit within limited budgets.
Cablevision Systems Corporation, together with its auxiliaries, owns and operates cable systems in the United States. The company operates through three segments: Cable, Lightpath, and Other.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
